Assessing potency and binding kinetics of soluble adenylyl cyclase (sAC) inhibitors to maximize therapeutic potential.

TitleAssessing potency and binding kinetics of soluble adenylyl cyclase (sAC) inhibitors to maximize therapeutic potential.
Publication TypeJournal Article
Year of Publication2022
AuthorsRossetti T, Ferreira J, Ghanem L, Buck H, Steegborn C, Myers RW, Meinke PT, Levin LR, Buck J
JournalFront Physiol
Volume13
Pagination1013845
Date Published2022
ISSN1664-042X
Abstract

In mammalian cells, 10 different adenylyl cyclases produce the ubiquitous second messenger, cyclic adenosine monophosphate (cAMP). Amongst these cAMP-generating enzymes, bicarbonate (HCO3 -)-regulated soluble adenylyl cyclase (sAC; ADCY10) is uniquely essential in sperm for reproduction. For this reason, sAC has been proposed as a potential therapeutic target for non-hormonal contraceptives for men. Here, we describe key sAC-focused in vitro assays to identify and characterize sAC inhibitors for therapeutic use. The affinity and binding kinetics of an inhibitor can greatly influence in vivo efficacy, therefore, we developed improved assays for assessing these efficacy defining features.

DOI10.3389/fphys.2022.1013845
Alternate JournalFront Physiol
PubMed ID36246105
PubMed Central IDPMC9554468
Grant ListP50 HD100549 / HD / NICHD NIH HHS / United States
R01 AG061290 / AG / NIA NIH HHS / United States
R01 HD088571 / HD / NICHD NIH HHS / United States